Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 9

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 9
---
 disclosure 
 of material information.                                                                                     |

In addition, our officers, directors and principal
shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act
and the rules under the Exchange Act with respect to their purchases and sales of our Ordinary Shares. Accordingly, an investor may receive
less information about us than it would receive about a public company incorporated in the United States.

Additionally, we elect to
follow certain home country corporate governance practices instead of those otherwise required under the listing rules of NASDAQ.

Additional Information

For additional information
related to our business and operations, please refer to the reports incorporated herein by reference, including our Annual Report on Form
20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and our Reports on Form 6-K, as filed with the SEC,
as described in the section titled “Incorporation of Certain Information by Reference.”

| 7 |

<div align='center'>The Offering</div>

| Depositary Shares offered by the Selling Shareholders                   |     | An aggregate of 4,349,102,800 Ordinary Shares of the Company represented by 10,872,757 Depositary Shares, consisting of (1) 5,329,783 Ordinary Shares represented by 2,131,913,200 Depositary Shares, issuable upon the exercise of Series J Warrants, (2) 5,329,783 Ordinary Shares represented by 2,131,913,200 Depositary Shares, issuable upon the exercise of Series K Warrants, and (3) 85,276,400 Ordinary Shares represented by 213,191 Depositary Shares, issuable upon the exercise of July 2024 Placement Agent Warrants. The selling shareholders are identified in the table commencing on page 65. |
| Total Ordinary Shares outstanding immediately prior to this offering    |     | 25,617,408,922 Ordinary Shares (including those represented by Depositary Shares) as of April 1, 2025.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Total Ordinary Shares to be outstanding immediately after this offering |     | 29,966,511,722 Ordinary Shares (including those represented by Depositary Shares), assuming all warrants are exercised in full.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Depositary Shares                                                       |     | Each Depositary Share represents 10,000 Ordinary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 Shares.